Log In
BCIQ
Print this Print this
 

ARN-6039

  Manage Alerts
Collapse Summary General Information
Company Arrien Pharmaceuticals LLC
DescriptionSmall molecule antagonist of RAR-related orphan receptor C thymus-specific isoform (RORgamma2; RORgammaT)
Molecular Target RAR-related orphan receptor C thymus-specific isoform (RORgamma2) (RORgammaT)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat multiple sclerosis (MS)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today